市場調查報告書
商品編碼
1576941
腦脊髓液管理的全球市場:洞察,競爭情形,市場預測:2030年Cerebrospinal Fluid Management - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
在 2024 年至 2030 年的預測期內,全球腦脊髓液管理市場規模預計將以 4.78% 的複合年增長率擴大。腦積水、腦腫瘤和顱內高壓等神經系統疾病的盛行率不斷增加,顯著增加了對先進腦脊髓液 (CSF) 管理系統的需求。此外,經常導致腦外傷的傷害和事故數量不斷增加,進一步推動了市場的發展。這些損傷需要有效的腦脊髓液管理,以更好地確保患者的治療結果。此外,預計從 2024 年至 2030 年,主要市場開發公司的持續產品開發活動正在帶來技術創新,增強腦脊髓液管理的功能和特性並提高患者安全。
根據 GLOBOCAN 提供的最新數據,預計 2022 年全球腦部和中樞神經系統癌症新發病例數預計為每 10 萬人中 322,000 例,到 2045 年預計將增至人均 474,000 例。
此外,根據世界衛生組織 (WHO) 的最新數據(2024 年),癲癇症影響著全球約 5,000 萬人,使其成為全球最受歡迎的神經系統疾病之一。近 80% 的受影響者生活在低收入和中等收入國家。
腦腫瘤等神經系統疾病常會擾亂正常的腦脊髓液流動和吸收,導致腦積水和顱內壓升高等症狀,從而顯著推動腦脊髓液管理市場的發展。這些疾病需要準確有效的腦脊髓液管理,以預防嚴重併發症並優化患者治療效果,從而促使全球腦脊髓液管理市場不斷擴大。
本報告提供全球腦脊髓液管理市場相關調查,提供市場概要,以及各產品類型,各年齡層,各終端用戶,各地區趨勢,及加入此市場的主要企業簡介等資訊。
Cerebrospinal Fluid Management Market by Product Type (CSF Shunts & Valves, External Drainage Systems [Drainage & Monitoring Systems, Drainage-Specific Systems, and CSF Drainage Catheters {Ventricular, Lumbar, and Others}], Anti-Siphon Devices, and Others), Age Group (Adult and Pediatric), End User (Hospitals and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of neurological conditions, increasing number of trauma & accidents, and increase in product development activities by key market players across the globe.
The global cerebrospinal fluid management market was valued at USD XX billion in 2023, growing at a CAGR of 4.78% during the forecast period from 2024 to 2030 to reach XX billion by 2030. The growing prevalence of neurological conditions like hydrocephalus, brain tumors, and intracranial hypertension is significantly boosting the demand for advanced cerebrospinal fluid (CSF) management systems. Additionally, the rise in trauma and accidents, which frequently result in traumatic brain injuries, is further driving the market, as these injuries require effective CSF management to ensure better patient outcomes. Furthermore, the ongoing product development activities by key market players are enhancing the capabilities and features of cerebrospinal fluid management, leading to innovations that improve patient safety further propelling the market growth during forecast period from 2024 to 2030.
Cerebrospinal Fluid Management Market Dynamics:
According to the recent data provided by the GLOBOCAN, in 2022, globally the estimated new cases of brain and central nervous system cancer was estimated to be 322,000 per 100,000 population and the projection were estimated to increase 474,000 per 100,000 population by 2045.
Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Nearly 80% of those affected reside in low- and middle-income countries.
Neurological disorders such as brain tumors significantly boost the market for cerebrospinal fluid management because they often lead to the disruption of normal cerebrospinal fluid flow or absorption, resulting in conditions like hydrocephalus or increased intracranial pressure. These disorders necessitate precise and effective management of cerebrospinal fluid to prevent severe complications and ensure optimal patient outcomes thereby escalating the overall market of cerebrospinal fluid management across the globe.
Additionally, as per the data provided by the World Health Organization (WHO) 2023, approximately 20 to 50 million people suffer from non-fatal road traffic accidents worldwide, every year. As road traffic accidents continue to be a leading cause of traumatic brain injuries worldwide, the demand for advanced cerebrospinal fluid management systems is expected to rise as when a severe head injury occurs, it can disrupt the normal flow and absorption of cerebrospinal fluid, leading to increased intracranial pressure and the risk of further complications hence, thereby escalating the overall market of cerebrospinal fluid management across the globe.
Along with the factors mentioned above, the increase in product development activities are also expected to aid in the growth of the cerebrospinal fluid management market. For instance, in March 2021, Anuncia Inc. received the ""Breakthrough Device Designation"" for ReFlow(TM) System Mini by the US FDA. The device is to be used in the treatment of CSF disorders requiring shunting such as hydrocephalus.
However, the stringent regulatory product approval process, common risks associated with the devices such as infection, shunt malfunction, and improper drainage, among others may hinder the growth of cerebrospinal fluid management.
Cerebrospinal Fluid Management Market Segment Analysis:
Cerebrospinal Fluid Management Market by Product Type (CSF Shunts & Valves, External Drainage Systems [Drainage & Monitoring Systems, Drainage-Specific Systems, and CSF Drainage Catheters {Ventricular, Lumbar, and Others}], Anti-Siphon Devices, and Others), Age Group (Adult and Pediatric), End User (Hospitals and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the overall cerebrospinal fluid management market, the CSF shunts & valves are expected to hold the largest share in the year 2023. CSF shunts and valves play a crucial role in boosting the overall market for cerebrospinal fluid (CSF) management systems by addressing the essential need for effective regulation of CSF flow in patients with conditions like hydrocephalus and intracranial hypertension. These devices are designed to divert excess cerebrospinal fluid from the brain's ventricles to other parts of the body, such as the abdominal cavity, where it can be safely absorbed. Their ability to provide targeted, long-term solutions for managing abnormal CSF accumulation has made them indispensable in clinical practice. Innovations in shunt and valve technology, such as improvements in biocompatibility, miniaturization, and programmable features, have enhanced their effectiveness and patient outcomes. This has led to increased adoption and demand for advanced CSF management systems across hospitals and clinics. As a result, the market for CSF management systems has experienced significant growth, driven by the need for more precise, reliable, and minimally invasive solutions to manage complex neurological conditions.
Additionally, the ongoing strategic activities across the globe further spurs the market of CSF shunts & valves. For instance, in May 2024, CereVasc received the FDA IDE approval for the STRIDE Pivotal study of the eShunt System for treatment of normal pressure hydrocephalus.
Hence, all the above-mentioned factors are expected to generate considerable revenue of the segment pushing the overall growth of the global cerebrospinal fluid management market during the forecast period.
North America is expected to dominate the overall cerebrospinal fluid management market:
Among all the regions, North America is expected to hold the largest share in the global cerebrospinal fluid management market in 2023. The growing prevalence of traumatic brain injuries, neurological disorders such as epilepsy, Alzheimer's, and Parkinson's disease across the region is escalating the overall market of cerebrospinal fluid management across the region. Additionally, recent product developmental activities, and rising government initiatives are expected to aid in the growth of the North American cerebrospinal fluid management market during the forecast period from 2024 to 2030.
As per the recent data provided by Centre for Disease Control and Prevention (2024), in 2021, there were more than 586 traumatic brain injury-related hospitalizations per day in the United States. Additionally, as per the recent data provided by the Alzheimer's Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Thus, these neurodegenerative conditions result in the progressive deterioration of brain cells, which can lead to disruptions in the normal production, circulation, or absorption of cerebrospinal fluid. Patients with advanced Parkinson's and Alzheimer's are more prone to develop hydrocephalus-a condition marked by the accumulation of cerebrospinal fluid in the brain's ventricles. This condition often requires the implantation of cerebrospinal fluid shunts or external drainage systems for management thereby escalating the overall market of cerebrospinal fluid management across the region.
Moreover, as per the recent data provided by the Centers for Disease Control and Prevention (2024) each year in United States, about 1,427 babies were born with spina bifida, or 1 in every 2,758 births in the country. Many babies born with spina bifida also develop hydrocephalus which may boost the demand for CSF management devices such as hydrocephalus shunts, eventually driving the CSF management market across the region growth during the forecast period.
Additionally, according to the recent data provided by the Brain Aneurysm Foundation (2024), an estimated 6.5 million people in the United States had an un-ruptured brain aneurysm. The annual rate of rupture in the country was approximately 8 - 10 per 100,000 people. About 30,000 people in the United States suffered a brain aneurysm rupture each year. A brain aneurysm ruptures every 18 minutes. It had been established that blood from a torn aneurysm can result in the blockage of CSF circulation leading to fluid buildup and increased pressure on the brain ultimately causing hydrocephalus. Therefore, the increase in number of patients suffering from brain aneurysms in the country is expected to drive the demand for CSF management devices, thereby contributing in the overall growth of the CSF management market in the North American region.
Furthermore, the increased emphasis on product development activities and high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for cerebrospinal fluid management. For instance, in July 2023, Anuncia Medical successfully launched second generation device, ReFlow(TM) Mini Flusher device, to treat hydrocephalus at several leading neurosurgical centers across the United States.
Therefore, the interplay of above mentioned various factors in the region are expected to boost the North America cerebrospinal fluid management market during the forecast period.
Cerebrospinal Fluid Management Market Key Players:
Some of the key market players operating in the cerebrospinal fluid management market include Medtronic PLC, B. Braun Melsungen AG, Neuromedex GmbH, Natus Medical Incorporated., Sophysa, Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, Desu Medical, Polyganics, CHRISTOPH MIETHKE GMBH & CO. KG, HpBio Proteses Inc., Wellong Instruments Co., Ltd., Moller Medical GmbH, CereVasc, Inc., Anuncia Inc., and others.
Recent Developmental Activities in the Cerebrospinal Fluid Management Market:
Key Takeaways From the Cerebrospinal Fluid Management Market Report Study:
Target Audience who can be Benefited From This Cerebrospinal Fluid Management Market Report Study:
Frequently Asked Questions for the Cerebrospinal Fluid Management Market: